Squamous cell lung cancer (SqCLC) is a distinct histologic subtype of NSCLC that is
challenging to treat because of specific clinicopathologic characteristics, which include older …

KRAS mutations are the most frequent gain-of-function alterations in patients with lung
adenocarcinoma (LADC) in the Western world. Although they have been identified decades …

Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are
being wildly used as target therapy in non-small-cell lung cancer (NSCLC). However …

Purpose To investigate the efficacy of erlotinib versus docetaxel in previously treated
patients with advanced non–small-cell lung cancer (NSCLC) in an epidermal growth factor …

Lung cancer is still the leading cause of cancer death worldwide. Both histologically and
molecularly lung cancer is heterogeneous. This review summarizes the current knowledge …

According to rapid development of chemotherapy in advanced non-small cell lung cancer
(NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually …

To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …

Docetaxel (Taxotere®) has been one of the most important chemotherapeutic drugs for
cancer treatment since 1996. Although a large number of clinical studies have been …

γδ T cells contribute to the front line of lymphoid antitumor surveillance and bridge the gap
between innate and adaptive immunity. They can be readily expanded to high numbers in …

Introduction The phosphatidylinositol 3-kinase (PI3K) pathway promotes tumor growth and
treatment resistance in non-small cell lung cancer (NSCLC). The aim of the open-label, two …